These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29025575)

  • 1. Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy.
    McMahon TJ; Bryan NS
    Am J Cardiol; 2017 Oct; 120(8S):S89-S95. PubMed ID: 29025575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Nitric Oxide Pathway in Pulmonary Vascular Disease.
    Klinger JR; Kadowitz PJ
    Am J Cardiol; 2017 Oct; 120(8S):S71-S79. PubMed ID: 29025573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related biomarkers in pulmonary hypertension.
    Swaminathan AC; Dusek AC; McMahon TJ
    Am J Respir Cell Mol Biol; 2015 Jun; 52(6):663-73. PubMed ID: 25611885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
    Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
    J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Modulation of Guanylate Cyclase Pathway Activity-Mechanism and Clinical Implications.
    Grześk G; Nowaczyk A
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34200064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of downstream target genes regulated by the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signal pathway in pulmonary hypertension.
    Zou L; Xu X; Zhai Z; Yang T; Jin J; Xiao F; Wang C
    J Int Med Res; 2016 Jun; 44(3):508-19. PubMed ID: 27048385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets.
    Lázár Z; Mészáros M; Bikov A
    Curr Med Chem; 2020; 27(42):7168-7188. PubMed ID: 32442078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
    Patel D; Lakhkar A; Wolin MS
    Adv Exp Med Biol; 2017; 967():227-240. PubMed ID: 29047089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling.
    Madhani M; Scotland RS; MacAllister RJ; Hobbs AJ
    Br J Pharmacol; 2003 Aug; 139(7):1289-96. PubMed ID: 12890708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nitric oxide/cGMP signaling pathway in pulmonary hypertension.
    Klinger JR
    Clin Chest Med; 2007 Mar; 28(1):143-67, ix. PubMed ID: 17338933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
    Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
    Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential alterations in responsiveness in particulate and soluble guanylate cyclases in pregnant guinea pig myometrium.
    Buhimschi IA; San Martin-Clark O; Aguan K; Thompson LP; Weiner CP
    Am J Obstet Gynecol; 2000 Dec; 183(6):1512-9. PubMed ID: 11120520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.
    Bice JS; Burley DS; Baxter GF
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):269-82. PubMed ID: 24572031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments.
    Piggott LA; Hassell KA; Berkova Z; Morris AP; Silberbach M; Rich TC
    J Gen Physiol; 2006 Jul; 128(1):3-14. PubMed ID: 16769793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
    Wilkins MR; Wharton J; Grimminger F; Ghofrani HA
    Eur Respir J; 2008 Jul; 32(1):198-209. PubMed ID: 18591337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.